Utilization Of Corticosteroids Research Articles

Ginkgo biloba extract prescriptions are associated with less frequent repeat visits to ENT doctors due to tinnitus: a retrospective cohort study

ObjectivesWe aimed to evaluate the drug utilization of Ginkgo biloba extract (Gbe), systemic corticosteroids (CSs), and pentoxifylline (PTXF) for the treatment of acute tinnitus by analyzing electronic patient health record data. In addition, we assessed whether the different drug treatments were associated with different frequencies of repeat visits to ear, nose, and throat (ENT) doctors.MethodsThis retrospective cohort study used data from the IQVIA Disease Analyzer (DA) database. It included patients with an initial diagnosis of tinnitus between January 2005 and December 2021, treated by ENT specialists in Germany.ResultsOf 111,629 patients meeting all selection criteria, 51,205 received prescriptions of Gbe, 34,817 of systemic CSs, and 25,607 of PTXF. Gbe prescription was associated with significantly lower odds of a repeat consultation due to tinnitus compared to systemic CSs [odds ratio (OR) 0.91; 95% confidence interval (CI): 0.88–0.95] as well as PTXF (OR 0.74; 95% CI: 0.72–0.77). This association was significant in both men and women and in some age groups.ConclusionGbe is the most frequently ENT specialist-prescribed drug for the treatment of acute tinnitus. It is associated with a reduced likelihood of patients consulting their ENT specialist for tinnitus again compared to systemic CSs and PTXF.

Intra-articular corticosteroid utilization and characterizations of use in juvenile idiopathic arthritis within the PR-COIN registry.

Intra-articular corticosteroid injections (IACI) have been shown to be effective at improving arthritis across juvenile idiopathic arthritis (JIA) categories. The American College of Rheumatology (ACR) recommends IACI use as primary and adjunctive therapy for JIA patients. However, there remains minimal data describing actual IACI use in North America. The objective of this study was to describe and to evaluate IACI use in JIA, utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) registry. Study participants from 13 sites were enrolled in the PR-COIN registry from 2011 to 2015. Demographic and clinical variables were summarized and Chi-squared and t-tests were used to evaluate differences between participants who did or did not receive IACI. Multiple logistic regression models were used to evaluate characteristics associated with IACI treatment. Our study included 3,241 participants, the majority of whom were white (85%), female (71%) and had oligoarticular JIA (39%). IACI was administered at least once in 23% of participants, the majority of whom had oligoarticular disease (52.5%), but overall use in oligoarticular participants was low at 30.8%. IACI use varied significantly between treatment centers and use was associated with oligoarticular disease, ANA positivity, and use of other systemic medications. This study demonstrates that participants with JIA enrolled in the PR-COIN registry between 2011 and 2015 with persistent oligoarticular disease, ANA positivity, and use of other systemic medications were more likely to receive IACI. However, IACI use was lower than expected for oligoarticular participants.

Glucocorticoidi intrarticolari nel trattamento del dolore da sublussazione d'anca in bambini con difetto cognitivo

The Authors report data from a study demonstrating the utility of intra-articular corticosteroids in treating pain from hip dysplasia in disabled children.

P.056 Real-world reduction in oral corticosteroid utilization following efgartigimod initiation in patients with generalized myasthenia gravis

Background: Reducing oral corticosteroids (OCS) use can alleviate the risk of many adverse events related to long-term OCS use. Here, we evaluate real-world utilization of OCS among patients with generalized myasthenia gravis (gMG) over the first 6 months following efgartigimod initiation. Methods: Patients with gMG using OCS who initiated efgartigimod treatment were identified retrospectively from an open US medical and pharmacy claims database (IQVIA Longitudinal Access and Adjudication Data [LAAD], April 2016-April 2023). Average daily dose (ADD) of OCS was analyzed during the 3-month period preceding efgartigimod initiation, and at 3 and 6 months post-efgartigimod initiation. Results: Of 231 patients assessed, 17 (7.4%), 109 (47.1%), and 105 (45.5%) had baseline OCS ADD of 0–5 mg, 5–20 mg, or >20 mg, respectively. At 3 and 6 months post-efgartigimod, 82 (35%) and 99 (43%) patients, respectively, reduced ADD by ≥5 mg. Proportion of patients with ADD of 0–5 mg increased >3-fold (7% baseline vs. 26% 6 months post-efgartigimod) and proportion of patients with ADD of >20 mg decreased by 35% (45% baseline vs. 29% 6 months post-efgartigimod) following efgartigimod initiation. Conclusions: Approximately 43% of patients were able to decrease steroid use or achieved steroid-free status within 6 months of efgartigimod treatment initiation.

Use of corticosteroids in non-infectious uveitis – expert consensus in Taiwan

Purpose To offer consensus on the utilization of corticosteroids (CS) for treating non-infectious uveitis in the context of clinical practice in Taiwan. This entails examining the different administration methods, their advantages and disadvantages, and considering alternative treatments according to the prevailing evidence and health policies. Methods Ten ophthalmologists and one rheumatologist convened on December 11, 2022, to review and discuss literature on the topic. The databases explored were the Central Cochrane library, EMBASE, Medline, PUBMED, and Web of Science using relevant keywords. The search spanned from January 1996 to June 2023. After the initial results of the literature review were presented, open voting determined the final statements, with a statement being accepted if it secured more than 70% agreement. This consensus was then presented at significant meetings for further discussions before the final version was established. Results A flow chart and nine statements emerged from the deliberations. They address the importance of CS in uveitis management, guidelines for using topical CS, indications for both periocular or intravitreal and systemic therapies, and tapering and discontinuation methods for both topical and systemic CS. Conclusion While CS are a cornerstone for non-infectious uveitis treatment, their administration requires careful consideration, depending on the clinical situation and the specific type of uveitis. The consensus generated from this article provides a guideline for practitioners in Taiwan, taking into account local health policies and the latest research on the subject. It emphasizes the significance of strategic tapering, the potential for alternative therapies, and the importance of patient-centric care.

Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study

Introduction: Healthcare costs and societal impact of myasthenia gravis (MG), a potentially life-threatening rare, chronic neuromuscular disease, are sparsely studied. We assessed healthcare resource utilization (HCRU) and associated costs among patients with newly diagnosed (ND) and preexisting (PE) MG in Sweden. Methods: This observational, retrospective cohort study used data from four linkable Swedish nationwide population-based registries. Adult MG patients receiving pharmacological treatment for MG and having ≥24-month follow-up during the period January 1, 2010, to December 31, 2017, were included. Results: A total of 1,275 patients were included in the analysis, of which 554 patients were categorized into the ND MG group and 721 into the PE MG group. Mean (±SD) age was 61.3 (±17.4) years, and 52.3% were female. In the first year post-diagnosis, ND patients had significantly higher utilization of acetylcholinesterase inhibitors (96.0% vs. 83.9%), corticosteroids (59.6% vs. 45.8%), thymectomy (12.1% vs. 0.7%), and plasma exchange (3.8% vs. 0.6%); had higher all-cause (70.9% vs. 35.8%) and MG-related (62.5% vs. 18.4%) hospitalization rates with 11 more hospitalization days (all p < 0.01) and an increased risk of hospitalization (odds ratio [95% CI] = 4.4 [3.43, 5.64]) than PE MG. In year 1 post-diagnosis, ND MG patients incurred EUR 7,302 (p < 0.01) higher total all-cause costs than PE MG, of which 84% were estimated to be MG-related and the majority (86%) were related to inpatient care. These results remained significant also after controlling for baseline demographics and comorbidities (p < 0.01). In year 2 post-diagnosis, the all-cause medical costs decreased by ∼55% for ND MG from year 1 and were comparable with PE MG. Conclusion: In this population-based study, MG patients required significantly more healthcare resources in year 1 post-diagnosis than PE MG primarily due to more pharmacological treatments, thymectomies, and associated hospitalizations. These findings highlight the need to better understand potential factors including disease characteristics associated with increased health resource use and costs and need for more efficacious treatments early in the disease course.

Real-world Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients Living with Generalized Myasthenia Gravis (S38.002)

Real-world Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients Living with Generalized Myasthenia Gravis (S38.002)

Assessing corticosteroid utilization and mortality risk in septic shock: insights from network meta-analysis

BACKGROUND: Despite current guidelines recommending corticosteroid administration in septic shock management, there is ongoing controversy regarding their impact on mortality rates and the most effective corticosteroid type. OBJECTIVES: To assess corticosteroid use and mortality risk in septic shock via network meta-analysis. METHODS: A comprehensive network meta-analysis was undertaken by retrieving articles from PubMed, Embase, and Scopus databases. Pertinent data encompassing baseline characteristics of articles, definitions of sepsis, types of corticosteroids employed, and mortality rates were systematically extracted from each article. The Manthel Hanzhel method alongside a network meta-analysis approach was employed to evaluate the influence of corticosteroid administration on mortality risk among individuals diagnosed with septic shock. RESULTS: Our analysis comprised a total of 50 articles. While indirect comparison failed to yield statistically significant results regarding the reduction in mortality risk, direct comparison indicated that corticosteroid administration was linked to a decreased risk of mortality among septic shock individuals (OR: 0.80; 95%CI: 0.68, 0.93; p Egger: 0.0550; p Heterogeneity: 0.0010; p: 0.0040). Furthermore, among all the types of corticosteroids analyzed, only the hydrocortisone and fludrocortisone combination demonstrated an association with reduced mortality risk in septic shock patients. Individuals receiving this combination therapy exhibited decreased likelihood of mortality compared to those receiving a placebo (OR: 0.78; 95%CI: 0.64, 0.96; p Egger: 0.3082; p Heterogeneity: 0.8570; p: 0.0190). CONCLUSION: Our study emphasizes the significance of corticosteroid therapy, particularly highlighting the hydrocortisone and fludrocortisone combination, for septic shock management.

A Study to Develop a Device to Aid in the Administration of Corticosteroid Nasal Spray to Improve Efficacy

Allergic rhinitis and chronic rhinosinusitis represent conditions stemming from two pivotal pathophysiological factors: hypersensitivity reactions and inflammation.(Bjermer et al., 2019; Liva et al., 2021; Nur Husna et al., 2022) Patients afflicted with chronic rhinosinusitis experience symptoms that profoundly impact their quality of life. (Sapsaprang et al., 2015) Consequently, treatment guidelines consistently advocate for the utilization of intranasal corticosteroids (INC) in cases of severe disease or disruptive symptoms. (Bousquet et al., 2020; Dykewicz et al., 2020; Emeryk et al., 2019; Scadding et al., 2017) However, clinical evidence suggests that during episodes of nasal mucosal inflammation, tissue edema can hinder the comprehensive dispersion of INC particles into deeper nasal recesses, thus impeding their therapeutic reach to affected regions. (Abdelhafeez, 2022; Rollema et al., 2022; Sher &amp; Ross, 2014) Conversely, presently available nasal spray formulations, particularly aqueous solutions commonly employed in Thailand, exhibit limitations in achieving efficient particle dispersion. Consequently, the effective delivery of INC is significantly contingent upon proper medication administration techniques, including bottle priming and synchronized inhalation during actuation. Literature reviews have divulged that many INC users frequently mismanage or inefficiently apply the medication, particularly during the actuation process.(Al-Rasheedi, 2023; May &amp; Dolen, 2019) Common issues include improper alignment of the nasal spray nozzle, inadequate force exerted during actuation, and failure to synchronize inhalation with medication release, collectively contributing to suboptimal treatment outcomes.

Policy, health facility and community implications of the findings of the study of illnesses in preterm (sip project): Summary recommendations from a dissemination workshop

The Study of Illness in Preterm (SIP) was designed in 2015 to identify the major causes of morbidity and mortality in preterm babies. Preterm complications are the commonest cause of neonatal mortality. The SIP study investigators in collaboration with Federal Ministry of Health-Ethiopia (FMOH) organized a dissemination workshop during the world prematurity day between Nov 17-18, 2021. &#x0D; The objective of the SIP dissemination workshop was to conduct a policy dialogue with policy makers and program implementers to support policy and practice changes. Five publications that have immediate policy and practice implications were selected and discussed in a dissemination workshop. These were hypothermia, preterm nutrition, bacterial isolates and antimicrobial resistance (AMR), antenatal corticosteroid utilization and respiratory distress syndrome (RDS). &#x0D; For each topic, the workshop assessed and documented the magnitude of the burden of disease, operationally feasible recommendations at policy, facility and community levels and potential implementation research ideas that could help facilitate rapid scale up of interventions.

Changes in Oral Corticosteroid Utilization in Patients with COPD Following Initiation of FF/UMEC/VI.

Oral corticosteroids (OCS) play a role in the treatment of acute chronic obstructive pulmonary disease (COPD) exacerbations; however, chronic use is not recommended due to the high rate of systemic complications, development of comorbidities, and increased mortality. Data assessing the real-world impact of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) on OCS utilization rates are limited. This study assessed the impact of FF/UMEC/VI on OCS use among patients with COPD previously treated with OCS. A retrospective database study of patients with COPD aged ≥40 years who initiated FF/UMEC/VI from 1 November 2017 to 31 December 2018, identified through the MarketScan® Commercial and Medicare Supplemental databases. Patients were required to have ≥1 dispensing of an OCS prior to initiation of FF/UMEC/VI (index) and were followed up for 12 months post-index. OCS utilization patterns, potential OCS-related adverse events, healthcare resource utilization (HCRU), and costs were compared between the 12-month pre- and post-index periods. A total of 2013 patients were identified (mean age 63.5 years, 55.7% female). The proportion of patients with ≥1 OCS claim decreased by 32.2% between the pre- and post-index period (67.8% vs 100%; p < 0.001). Comparing the post-index period to the pre-index period, mean number of OCS pharmacy claims per patient decreased from 3.3 to 2.5 (p < 0.001) and mean daily dose was reduced from 3.1 to 2.6 mg/day (p = 0.004); 30.0% of patients reduced their daily dose by 90-100%. Reductions were also seen in COPD-related HCRU. The proportion of patients with an inpatient admission for COPD decreased from 11.4% to 7.1% (p < 0.001), emergency room visits decreased from 23.1% to 17.4% (p < 0.001), and office visits from 97.5% to 90.1% (p < 0.001). Similar results were seen for all-cause HCRU. Among patients with COPD with prior OCS use, FF/UMEC/VI initiation resulted in significant reductions in OCS utilization, COPD-related HCRU (including hospitalization), and all-cause HCRU.

E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Continues: An Opportunity for Pharmacist Intervention.

Electronic cigarette (e-cigarette), or vaping, product use-associated lung injury (EVALI) was first identified and reported in 2019, but media coverage and reporting of cases drastically decreased when the COVID-19 pandemic started in early 2020. The syndrome has continued to occur since that time and it is critical that pharmacists are aware of how EVALI presents, and when it should be considered as a potential diagnosis. Inpatient and outpatient pharmacists play a vital role in the treatment of EVALI, and should be knowledgeable of the utility of corticosteroids, even though data are extremely limited. Pharmacists should understand the importance of collecting detailed and accurate information about vaping from patient interviews. Pharmacists also play a leading role in cessation counseling and treatment, selecting medications that can be used to treat nicotine addiction from vaping, and assisting with transitions of care and follow-up.

COVID-19-associated mucormycosis in India: Why such an outbreak?

An unprecedented mucormycosis outbreak occurred in India during the second COVID-19 wave in spring 2021. COVID-19-associated mucormycosis (CAM) was observed, mainly rhino-orbito-cerebral mucormycosis (ROCM), in patients with poorly controlled diabetes and treated with inappropriate doses of glucocorticoids. The aim of this mini-review was to compare the characteristics of the CAM epidemic in India with (i) mucormycosis cases before the COVID-19 pandemic and (ii) CAM in the rest of the world (particularly in France) in order to identify the reasons for this outbreak. In India, the major mucormycosis epidemiologic change during the COVID-19 pandemic was an increase in the percentage of patients treated with corticosteroids who developed CAM. Compared with the rest of the world, India reported a higher mucormycosis incidence even before the COVID-19 pandemic. Moreover, in India, patients with CAM were more likely to have diabetes mellitus and ROCM; conversely, mortality rates were lower. The reasons for such a localized epidemic in India have remained unclear, but some hypotheses can be put forward, particularly the combination of high prevalence of uncontrolled diabetes mellitus and frequent indiscriminate corticosteroid utilization in a country that already had a high mucormycosis burden before the COVID-19 pandemic.

Postnatal corticosteroid exposure in very preterm infants: A French cohort study.

Background: Postnatal corticosteroids (PC) are widely used in very preterm infants. International reports and national multicenter trials describe a marked variability across countries and inter-sites, in the use of PC. Few information is available on therapeutic indications and prescription characteristics of PC. Aim: The main objective of this study was to describe the exposure to PC in a large cohort of preterm infants born at less than 32weeks of gestation, according to the prescription data of 41 tertiary-care NICUs in France. Secondary objectives were to describe therapeutic indications, day of life (DOL) of the first exposure, route of administration, duration, cumulative dose for each drug, and differences in exposure rates across centers. Methods: We conducted a prospective observational cohort analysis from January 2017 to December 2021, in 41 French tertiary-care NICUs using the same computerized order-entry system. Results: In total, 13,913 infants [birth weight 1144.8 (±365.6) g] were included. Among them, 3633 (26.1%) were exposed to PC, 21.8% by systemic and 10.1% by inhaled route. Within the study population, 1,992 infants (14.3%) received the first corticosteroid treatment in the first week of life and 1641 (11.8%) after DOL 7. The more frequent indications were prevention and/or treatment of bronchopulmonary dysplasia, and arterial hypotension. Hydrocortisone was the more often prescribed molecule. For systemic PC the first exposure occurred in mean at DOL 9.4 (±13.5), mean duration of treatment was 10.3 (±14.3) days, and the cumulative dose (expressed as the equivalent dose of hydrocortisone) was in median [IQR] 9.0 [5.5-28.8] mg/kg. For inhaled PC, the first exposure occurred in mean at DOL 34.1 (±19.7), and mean duration of treatment 28.5 (±24.4) days. The exposure rate ranged from a minimum of 5% to a maximum of 56% among centers, and significantly increased over the study period (p < 0.0001). Conclusion: In this French cohort of very preterm infants, around one patient out to five was exposed to PC during hospital stay in the NICU. The exposure occurred early, starting from the first week of life. Exposure rate widely varied among centers. Pharmacoepidemiology studies are useful to increase knowledge on corticosteroid utilization patterns in preterm infants.

A Prospective Study On Corticosteroids Utilization Pattern In Dermatology Department Of A Tertiary Care Teaching Hospital, Bangalore, India

Corticosteroids are widely prescribed in dermatology department and a rational prescribing lead to maximum benefit and minimum untoward effects. The objectives of this study were to assess the corticosteroid prescribing pattern for various skin diseases and to identify, monitor and assess any drug interactions and adverse reactions if any associated with their use. A prospective cross-sectional study on corticosteroid utilization pattern in dermatology department of a tertiary care teaching hospital was done by reviewing 205 inpatient cases for a period of 6 months. The data was collected with respect to demographics, medical and medication history, laboratory data and drugs prescribed during hospitalization and at discharge. A descriptive statistical analysis was performed to report the findings in terms of number and percentage. Corticosteroids were prescribed in 129 cases with 72male patients most in 51-60-year age group and 57female patients with 28% in 31-40-year age group. The common indications were psoriasis, dermatitis, and pemphigus. Prednisolone (27.4%) followed by clobetasol (22.04%) were most commonly prescribed. 48.6% therapy was by topical route, 28.2% by oral and 23.03% parenteral route. At discharge prednisolone and clobetasol were mostly prescribed and topical route was the most preferred route. Drug interactions involving drugs like betamethasone, triamcinolone, dexamethasone, and prednisolone were observed but no adverse reactions were reported. With a wide choice of corticosteroids and dosage forms available to treat dermatological conditions the rational therapy should consider the appropriate choice of drugs, potency, effectiveness and the cost.

Vitiligo evidence-based expert consensus recommendations for paediatric and adolescent patients: part I—topical therapeutics

Abstract No United States paradigm for the treatment of paediatric, adolescent and young adult vitiligo has been developed. To develop evidence and consensus-based expert opinion to promote therapeutic consistency for the diagnosis and treatment of vitiligo. An IRB-exempted process was developed to produce consensus recommendations based on literature review and SORT criteria. Research questions were reviewed on 9 May 2022 in a video-based conference. Forty-two recommendations were made on the diagnosis of vitiligo (5) and optimal topical therapeutics (37). Topical calcineurin inhibitors, topical corticosteroids and topical ruxolitinib 1·5% cream were all identified as potential first-line therapies in the management of paediatric and adolescent patients with specific guidance on age-based data, frequency of application, minimum length of the therapeutic trial and coordinated usage of ultraviolet light therapy. The literature on paediatric and adolescent vitiligo has a heterogeneous methodology and lack of patient-reported outcomes. Children with vitiligo may be effectively managed with a variety of topical agents as first- and second-line therapy. Evidence supports the utility of topical calcineurin inhibitors, topical corticosteroids and topical JAK inhibitors, with limitations based on factors such as location, body surface area and age.

Inflammatory bowel disease in pediatrics

Inflammatory bowel disease (IBD) comprises of Crohn’s disease (CD) and ulcerative colitis (UC). This is a chronic inflammation involving gastrointestinal tract. The prevalence of IBD is increasing recently. Approximately, 25% of all IBD cases develope during childhood. Intrinsic and extrinsic factors play important role in the pathogenesis of IBD. Mild form of IBD is more common in children with symptoms ranging from weight loss, rectal bleeding, diarrhea, and abdominal pain. Diagnosis is established based on history, physical examination, laboratory examination, imaging, endoscopy and colonoscopy, and ultimately, histopathology examination. Management includes utilization of aminosalicylates, corticosteroids, immunomodulators, and biologic agents. Nutritional support, psychosocial approach and surgical approach are other therapeutic options. The complications may occur such as micronutrient deficiency, growth failure, increased risk of malignancies, and psychiatric disorders. Routine monitoring of disease progress and growth achievement is mandatory in the management of IBD.

Evaluating the utility of screening corticosteroids found in standard/baseline patch testing series

Evaluating the utility of screening corticosteroids found in standard/baseline patch testing series

1213: A COMPARISON OF CORTICOSTEROIDS VERSUS VASOPRESSIN AS A SECOND-LINE ADD-ON AGENT IN SEPTIC SHOCK

Introduction: First-line hemodynamic support and the vasopressor of choice for septic shock is norepinephrine. There is considerable variability in practice and a paucity of data regarding when to add vasopressin or corticosteroids, and in what sequence. Defining which agent to administer secondarily to norepinephrine for escalation of hemodynamic support could reduce unnecessary adverse events from central line utilization, decrease adverse drug events, and may result in more economic management of patients. Methods: This is a single-center, retrospective cohort study of patients admitted to the intensive care unit (ICU) between October 2020 and January 2021. Patients were included if > 18 years of age and received norepinephrine plus either vasopressin or corticosteroids as second-line support for septic shock. Patients were excluded if they were on corticosteroids prior to admission. The primary outcome was the percentage of patients who required escalation of hemodynamic support after receipt of a second-line agent within 2 hours. Secondary outcomes included ICU length of stay (LOS), hospital LOS, in-hospital mortality, total hours on vasopressors, acute kidney injury (AKI), need for dialysis and/or renal replacement therapy, superinfection > 48 hours from time zero, and central line utilization. Results: Of 1287 patients screened for inclusion, 142 patients were included in the primary analysis. Eighty-three patients received vasopressin first, 43 patients received corticosteroids first, and 13 patients received both vasopressin and corticosteroids at the same time. For the primary outcome, 15.7%, 32.6%, 7.7% required escalation of norepinephrine within 2 hours, respectively. Respectively, mortality rates were 62.7%, 65.1%, and 76.9%. Central line utilization was on average 12.5 days, 6.6 days, and 5 days among the respective groups. Conclusions: There exists a lack of data when examining the utilization of vasopressin and corticosteroids as second-line add-on agents in septic shock. There was a higher mortality rate than expected among the population who received both corticosteroids and vasopressin at the same time. Central line utilization was lower in those who received corticosteroids first and for those who received both at the same time.

Quality of Life Among Children with Inflammatory Bowel Disease in Saudi Arabia: A Cross-Sectional Study.

The aim of this study was to investigate the quality of life in children and adolescents aged 7-18 years with inflammatory bowel disease and identify the factors that influence it. A multi-center cross-sectional study in which participants were recruited from 3 governmental hospitals in the Eastern Province of Saudi Arabia. A total of 61 children with inflammatory bowel disease were approached, 44 participants were included according to their age (7-18 years), disease duration of at least 6 months, and without any other co-morbidities. A translated Arabic version of the IMPACT-III questionnaire was used to assess the quality of life of the participants with inflammatory bowel disease. In addition, disease-specific indices were used to measure their disease activity; Harvey Bradshaw for patients with Crohn's disease and Pediatric Ulcerative Colitis Activity Index for ulcerative colitis patients. The mean age of the 44 participants was 13.36 ± 2.85. Crohn's disease accounted for 56.8% of the sample, while 36.4% had ulcerative colitis and 6.8% had unclassified type. The majority were males and in disease remission. The mean total score of the questionnaire was 74.10 ± 12.21, where the domain of social functioning scored the highest and the domain of emotional functioning scored the lowest. Children who are 11 years or older scored significantly higher in emotional functioning and total mean scores. Statistical significance was also observed between the well-being domain and not having flare-ups in the past year, as well as disease severity with emotional functioning, body image, and total mean scores. It was found that corticosteroid utilization is a predictor of poorer quality of life and was statistically significant with the body image domain. Measuring the quality of life in children with inflammatory bowel disease can aid in reducing its burden and help address its factors.